Valeant Pharmaceuticals Completes Sale Of Filler And Toxin Assets To Galderma

Valeant Pharmaceuticals Completes Sale Of Filler And Toxin Assets To Galderma

10 July 2014

Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has completed the sale to Galderma of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash, pursuant to the previously announced agreement with Nestle S.A, which recently completed its acquisition of Galderma.

"We are pleased to complete the divestiture of our products to a company that is firmly committed to the aesthetic dermatology market," said J. Michael Pearson, chairman and chief executive officer. "Humberto Antunes, CEO of Galderma, has embraced our commercial team and I know he will continue our efforts to build strong relationships with the healthcare leaders in this industry."

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Contact Information:
Laurie W. Little
949-461-6002
[email protected]


Meghan Gavigan | Sard Verbinnen & Co
630 Third Avenue | New York, NY 10017
T: 212.687.8080 | F: 212.687.8344

Suggested Articles

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.

Eli Lilly and Boehringer's Jardiance fell short in a heart failure trial in patients with or without diabetes—a test AZ's rival Farxiga recently aced.

House Democrats passed Pelosi's drug pricing bill, named after the late Rep. Elijah Cummings, in a mostly party-line vote Thursday.